JP7229538B2 - 薬物標的を特定するための細胞型特異的プロファイリング方法 - Google Patents

薬物標的を特定するための細胞型特異的プロファイリング方法 Download PDF

Info

Publication number
JP7229538B2
JP7229538B2 JP2019543339A JP2019543339A JP7229538B2 JP 7229538 B2 JP7229538 B2 JP 7229538B2 JP 2019543339 A JP2019543339 A JP 2019543339A JP 2019543339 A JP2019543339 A JP 2019543339A JP 7229538 B2 JP7229538 B2 JP 7229538B2
Authority
JP
Japan
Prior art keywords
nuclei
cell
expression
genes
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019543339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508652A5 (https=
JP2020508652A (ja
Inventor
ハインツ，ナサニエル
シュウ，シャオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JP2020508652A publication Critical patent/JP2020508652A/ja
Publication of JP2020508652A5 publication Critical patent/JP2020508652A5/ja
Priority to JP2023017878A priority Critical patent/JP7604014B2/ja
Application granted granted Critical
Publication of JP7229538B2 publication Critical patent/JP7229538B2/ja
Priority to JP2024211757A priority patent/JP2025032204A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Artificial Intelligence (AREA)
JP2019543339A 2017-02-10 2018-02-09 薬物標的を特定するための細胞型特異的プロファイリング方法 Active JP7229538B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023017878A JP7604014B2 (ja) 2017-02-10 2023-02-08 薬物標的を特定するための細胞型特異的プロファイリング方法
JP2024211757A JP2025032204A (ja) 2017-02-10 2024-12-04 薬物標的を特定するための細胞型特異的プロファイリング方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762457420P 2017-02-10 2017-02-10
US62/457,420 2017-02-10
US201762558396P 2017-09-14 2017-09-14
US62/558,396 2017-09-14
PCT/US2018/017556 WO2018148501A1 (en) 2017-02-10 2018-02-09 Methods for cell-type specific profiling to identify drug targets

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023017878A Division JP7604014B2 (ja) 2017-02-10 2023-02-08 薬物標的を特定するための細胞型特異的プロファイリング方法

Publications (3)

Publication Number Publication Date
JP2020508652A JP2020508652A (ja) 2020-03-26
JP2020508652A5 JP2020508652A5 (https=) 2021-03-18
JP7229538B2 true JP7229538B2 (ja) 2023-03-01

Family

ID=63107837

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019543339A Active JP7229538B2 (ja) 2017-02-10 2018-02-09 薬物標的を特定するための細胞型特異的プロファイリング方法
JP2023017878A Active JP7604014B2 (ja) 2017-02-10 2023-02-08 薬物標的を特定するための細胞型特異的プロファイリング方法
JP2024211757A Pending JP2025032204A (ja) 2017-02-10 2024-12-04 薬物標的を特定するための細胞型特異的プロファイリング方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023017878A Active JP7604014B2 (ja) 2017-02-10 2023-02-08 薬物標的を特定するための細胞型特異的プロファイリング方法
JP2024211757A Pending JP2025032204A (ja) 2017-02-10 2024-12-04 薬物標的を特定するための細胞型特異的プロファイリング方法

Country Status (11)

Country Link
US (1) US12577609B2 (https=)
EP (2) EP3580338B1 (https=)
JP (3) JP7229538B2 (https=)
CN (2) CN110582578B (https=)
AU (2) AU2018219308B2 (https=)
CA (1) CA3052290A1 (https=)
ES (1) ES2992087T3 (https=)
IL (1) IL268417B2 (https=)
MX (2) MX2019009612A (https=)
SG (1) SG11201907162TA (https=)
WO (1) WO2018148501A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152543A1 (en) * 2018-01-31 2019-08-08 Dovetail Genomics, Llc Sample prep for dna linkage recovery
WO2020037311A1 (en) * 2018-08-17 2020-02-20 University Of Florida Research Foundation, Inc. Protein and peptide biomarkers for traumatic injury to the central nervous system
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
JP2022544496A (ja) * 2019-08-12 2022-10-19 ミッション バイオ インコーポレイテッド 同一のシングルセルにおける、タンパク質発現、一塩基変化、及びコピー数多型のマルチオミクス同時検出のための方法、システム、及び装置
CN114375328B (zh) * 2019-09-06 2024-12-27 学校法人庆应义塾 包含胶质前体细胞的细胞聚集体的制备方法
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
CN110699362B (zh) * 2019-11-15 2023-03-24 兰州理工大学 Afp5基因及其应用
CN111312330A (zh) * 2020-02-13 2020-06-19 兰州理工大学 一种基于蛋白质节点特性的关键蛋白质识别方法及系统
EP4146831A4 (en) * 2020-05-06 2024-05-15 Dignity Health SYSTEMS AND METHODS FOR TREATING LEVODOPA-INDUCED DYSKINESIA, IMPROVING MOTOR BENEFITS AND DELAYING DISEASE PROGRESSION
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN112538480B (zh) * 2020-12-24 2022-09-27 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 精子鞭毛多发形态异常疾病动物模型的构建方法和应用
CN112522425B (zh) * 2020-12-25 2023-11-28 武汉睿健医药科技有限公司 Dpc细胞鉴定分类用标记物基因、筛选方法及应用
CN112481273B (zh) * 2020-12-29 2023-11-24 南通大学附属医院 结直肠癌抑癌基因及其启动子区高dna甲基化的验证方法
CN113186281B (zh) * 2021-04-02 2023-02-28 广州医科大学附属第五医院 作为肝细胞癌标志物的inava
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
US11946928B2 (en) * 2021-05-20 2024-04-02 Trustees Of Boston University Methods and compositions relating to airway dysfunction
US20240254514A1 (en) * 2021-05-21 2024-08-01 Allen Institute Artificial expression constructs for modulating gene expression in neurons within the thalamus
CN113495167B (zh) * 2021-06-24 2024-05-03 迈克医疗电子有限公司 血细胞分析仪的试剂加载方法及装置
CN113558011B (zh) * 2021-07-23 2022-05-10 深圳市中医院 基于γ-分泌酶激活蛋白基因的干燥综合征动物模型的建立方法
CN113652486B (zh) * 2021-09-13 2023-02-03 新疆医科大学第四附属医院 结直肠癌治疗预后生物标志物及其应用
CN113893892B (zh) * 2021-11-10 2023-02-10 大连海事大学 一种基于微流控芯片的纳米孔及其制备方法
CN114276993A (zh) * 2021-11-11 2022-04-05 上海昆盟生物科技有限公司 一种用于分离大鼠下丘脑弓状核神经元的方法
CN116297884A (zh) * 2021-12-01 2023-06-23 中国科学院大连化学物理研究所 一种基于mrm技术对工程菌株mva途径多靶标蛋白质的检测方法
CN114457075B (zh) * 2021-12-15 2023-05-02 徐州市中心医院 一种敲低PXYLP1基因表达的shRNA、慢病毒载体及其构建方法和应用
US20230191222A1 (en) * 2021-12-21 2023-06-22 Shuhari Group, LLC Impact And Movement Sensing To Measure Performance
CN114807124B (zh) * 2022-04-01 2023-09-12 上海信诺佰世医学检验有限公司 一种检测alk融合基因的引物和探针组合物、试剂盒及方法
CN114751990B (zh) * 2022-04-01 2023-10-20 中国科学技术大学 酰胺高丝氨酸内酯受体-增强绿色荧光融合蛋白及其制备方法与应用
EP4518871A1 (en) * 2022-05-05 2025-03-12 Alnylam Pharmaceuticals, Inc. Actin-binding lim protein 3 (ablim3) irna agent compositions and methods of use thereof
CN115096978B (zh) * 2022-05-26 2025-06-27 核工业理化工程研究院 一种稳定同位素丰度的质谱测定方法
CN114875033A (zh) * 2022-06-29 2022-08-09 福建省医学科学研究院 sgRNA、CRISPR/Cas试剂及其应用
CN115161260B (zh) * 2022-07-01 2023-07-14 中国人民解放军空军军医大学 Mal-PEG6-NHS-ester在外泌体示踪修饰中的应用和外泌体修饰的方法
CN115083522B (zh) * 2022-08-18 2022-10-28 天津诺禾致源生物信息科技有限公司 细胞类型的预测方法、装置及服务器
CN115508176A (zh) * 2022-09-30 2022-12-23 昆明理工大学 一种基于非标记的三七总皂苷治疗神经退行性疾病的靶点筛选方法
CN116004773B (zh) * 2022-09-30 2025-04-08 华南农业大学 一种线性置换等温扩增方法及其应用
CN116144655A (zh) * 2022-10-12 2023-05-23 中国农业科学院兰州兽医研究所 一种瞬时靶向干扰HS3ST5基因表达的siRNA及其应用
CN115850516B (zh) * 2022-11-16 2024-06-11 西北农林科技大学 鱼类蛋白自组装纳米抗原及其制备的疫苗与应用
CN115927596A (zh) * 2022-12-02 2023-04-07 中国科学技术大学 一种用于诊断小鼠小脑衰老的生物标记物及其应用
CN121889502A (zh) * 2023-04-06 2026-04-17 科洛索生物科学有限公司 长毛猛犸象特异性基因变体及包含其的组合物
CN121693563A (zh) * 2023-04-13 2026-03-17 5端生物科技股份有限公司 上调逆转录和降低rna测序中序列偏好性的组合物和方法
CN117590001A (zh) * 2023-11-22 2024-02-23 厦门大学 外泌体tmem176b在制备诊断肿瘤的药物中的用途
CN117925846B (zh) * 2024-03-25 2024-06-11 包头市中心医院 一种用于胃癌预后评价的生物标记物及其应用
CN118726571B (zh) * 2024-07-23 2025-02-14 南京市第一医院 主动脉夹层分子标志物及其应用
CN119804865B (zh) * 2024-12-31 2025-10-24 郑州大学 细胞外囊泡蛋白质作为诊断腹主动脉瘤的生物标志物及应用
CN119614700B (zh) * 2025-02-13 2025-06-10 南昌大学第一附属医院 MybpC1基因/蛋白在制备骨关节炎药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105854A2 (en) 2011-01-31 2012-08-09 Curonz Holdings Company Limited Compositions for administration to the eye

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936582B1 (en) * 1997-09-09 2005-08-30 Curis, Inc. Synergistic effects of OP/BMP morphogens and GDNF/NGF neurotrophic factors
ES2277567B1 (es) * 2005-12-30 2008-06-01 Universidad Del Pais Vasco Compuestos con propiedades neuroprotectoras.
WO2009087139A1 (en) 2008-01-04 2009-07-16 Centre National De La Recherche Scientifique Molecular in vitro diagnosis of breast cancer
JP5670755B2 (ja) 2008-03-12 2015-02-18 ザ ロックフェラー ユニバーシティ 翻訳プロファイリング及び分子表現型解析のための方法及び組成物
US9758809B2 (en) * 2013-03-06 2017-09-12 Emory University RNA splicing alterations and U1 small nuclear ribonucleoproteins in neurodegenerative diseases
EP3031929A1 (en) * 2014-12-11 2016-06-15 Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch Genome architecture mapping

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105854A2 (en) 2011-01-31 2012-08-09 Curonz Holdings Company Limited Compositions for administration to the eye

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Eric B. Dammer et al.，Neuron enriched nuclear proteome isolated from human brain.，J. Proteome Res. ，2013年07月05日，Vol.12, No.7，p.3193-3206，doi: 10.1021/pr400246t
Guang Bai et al.，Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains.，Hum. Mol. Genet.，2015年03月01日， Vol. 24, No. 5，p.1441-1456，doi: 10.1093/hmg/ddu561

Also Published As

Publication number Publication date
JP2023058610A (ja) 2023-04-25
EP3580338A1 (en) 2019-12-18
EP4461818A2 (en) 2024-11-13
MX2024000814A (es) 2024-02-06
JP2025032204A (ja) 2025-03-11
EP3580338C0 (en) 2024-09-11
IL268417B1 (en) 2025-01-01
ES2992087T3 (es) 2024-12-09
MX2019009612A (es) 2019-11-12
IL268417A (en) 2019-09-26
US20210095334A1 (en) 2021-04-01
CN110582578B (zh) 2024-02-02
CN117965689A (zh) 2024-05-03
CN110582578A (zh) 2019-12-17
EP3580338A4 (en) 2021-05-26
EP3580338B1 (en) 2024-09-11
WO2018148501A1 (en) 2018-08-16
US12577609B2 (en) 2026-03-17
IL268417B2 (en) 2025-05-01
AU2018219308A1 (en) 2019-08-22
JP7604014B2 (ja) 2024-12-23
EP4461818A3 (en) 2025-02-12
SG11201907162TA (en) 2019-09-27
AU2024259851A1 (en) 2024-12-12
CA3052290A1 (en) 2018-08-16
AU2018219308B2 (en) 2024-08-08
JP2020508652A (ja) 2020-03-26

Similar Documents

Publication Publication Date Title
JP7604014B2 (ja) 薬物標的を特定するための細胞型特異的プロファイリング方法
Li et al. Single-cell brain organoid screening identifies developmental defects in autism
Kim et al. Single-nucleus transcriptomics reveals functional compartmentalization in syncytial skeletal muscle cells
Clark et al. Single-cell RNA-seq analysis of retinal development identifies NFI factors as regulating mitotic exit and late-born cell specification
Xu et al. Species and cell-type properties of classically defined human and rodent neurons and glia
US20220411783A1 (en) Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
Simpson et al. Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer’s pathology and APOE genotype
Spiteri et al. Identification of the transcriptional targets of FOXP2, a gene linked to speech and language, in developing human brain
Lu et al. Tracking cell-type-specific temporal dynamics in human and mouse brains
Carosso et al. Precocious neuronal differentiation and disrupted oxygen responses in Kabuki syndrome
WO2016103269A1 (en) Populations of neural progenitor cells and methods of producing and using same
Jeffries et al. Single-cell transcriptomic and genomic changes in the ageing human brain
Rexach et al. Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics
AU2013295732A1 (en) Screening, diagnosis and prognosis of autism and other developmental disorders
CN109837340B (zh) 用于肺癌无创诊断的外周血基因标记物
Osheroff et al. Gene expression profiling of preplate neurons destined for the subplate: genes involved in transcription, axon extension, neurotransmitter regulation, steroid hormone signaling, and neuronal survival
EP3271485A1 (en) Methods for diagnosing and treating follicular lymphoma
Kolson et al. Temporal patterns of gene expression during calyx of held development
Kim et al. Boosting of tau protein aggregation by CD40 and CD48 gene expression in Alzheimer's disease
CA3074791A1 (en) Novel cell line and uses thereof
Yen et al. MYT1L deficiency impairs excitatory neuron trajectory during cortical development
HK40118624A (en) Methods for cell-type specific profiling to identify markers for nuclei isolation
HK40011621B (en) Methods for cell-type specific profiling to identify markers for nuclei isolation
HK40011621A (en) Methods for cell-type specific profiling to identify markers for nuclei isolation
Williams Transcriptomic and Epigenomic Analysis Reveals Convergent Synaptic Deficits in Alzheimer’s Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191101

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20191002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230208

R150 Certificate of patent or registration of utility model

Ref document number: 7229538

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250